Vinblastine



Vinblastine
Systematic (IUPAC) name
 ?
Identifiers
CAS number 865-21-4
ATC code L01CA01
PubChem 8935
DrugBank APRD00708
Chemical data
O9 
Mol. mass 810.974 g/mol
Pharmacokinetic data
Bioavailability n/a
CYP3A4-mediated)
Half life 24.8 hours (terminal)
Excretion Biliary and renal
Therapeutic considerations
Pregnancy cat.

D(AU) D(US)

Legal status

℞-only(US)

Routes Exclusively intravenous

 

Vinblastine is an anti-mitotic drug used to treat certain kinds of cancer, including Hodgkin's lymphoma, non-small cell lung cancer, breast cancer and testicular cancer.

History

Vinblastine was first isolated by Robert Noble and Madagascar periwinkle plant. Vinblastine's utility as a chemotherapeutic agent was first discovered when it was crushed into a tea. Consumption of the tea led to a decreased number of white blood cells; therefore, it was hypothesized that vinblastine might be effective against cancers of the white blood cells such as lymphoma.

Pharmacology

Vinblastine is a vinca alkaloid and a chemical analogue of vesicant (blister-forming) activity, and extravasation injury (forms deep ulcers).

Vinblastine paracrystals may be comprised of tightly-packed unpolymerized tubulin or microtubules.[1]

Indications

Vinblastine is a component of a number of ABVD for Hodgkin lymphoma. It is also used to treat histiocytosis according to the established protocols of the Histiocytosis Association of America.

See also

v • d • e
Mitotane
 
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Vinblastine". A list of authors is available in Wikipedia.